Engagement of the B cell receptor for antigen differentially affects B cell responses to Toll-like receptor-7 agonists and antagonists in BXSB mice

Clinical and Experimental Immunology

Volumn 163, Issue 3, 2011, Pages 392-403

  Layer, T ^a   Steele, A ^a   Goeken, J A ^a   Fleenor, S ^a   Lenert, P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

B cell receptor for antigen; B cells; SLE; Toll like receptors

Indexed keywords

B LYMPHOCYTE RECEPTOR; CL 075; CL 097; IMIQUIMOD; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 6; LOXORIBINE; NUCLEASE; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL PROTECTION; CYTOKINE RELEASE; FEMALE; IC 50; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; QUINOLINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; THIAZOLES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 79551696318     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04307.x     Document Type: Article

References (77)

1. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93-151.
2. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303-6.
3. Lenert P. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. Clin Exp Immunol 2010; 161:208-22.
4. Roberts TL, Idris A, Dunn JA etal. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323:1057-60.
5. Hornung V, Ablasser A, Charrel-Dennis M etal. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-18.
6. Takaoka A, Wang Z, Choi MK etal. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448:501-5.
7. Wang Z, Choi MK, Ban T etal. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA 2008; 105:5477-82.
8. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009; 10:1065-72.
9. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009; 138:576-91.
10. Ishii KJ, Coban C, Kato H etal. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7:40-8.
11. Yoneyama M, Kikuchi M, Natsukawa T etal. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5:730-7.
12. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. MDA-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 2002; 99:637-42.
13. Kato H, Takeuchi O, Sato S etal. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441:101-5.
14. Allam R, Pawar RD, Kulkarni OP etal. Viral 5'-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur J Immunol 2008; 38:3487-98.
15. Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001; 22:427-31.
16. Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheum 2004; 16:541-7.
17. Yasuda K, Yu P, Kirschning CJ etal. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol 2005; 174:6129-36.
18. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8.
19. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31.
20. Heil F, Hemmi H, Hochrein H etal. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-9.
21. Hemmi H, Takeuchi O, Kawai T etal. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5.
22. Häcker H, Mischak H, Miethke T etal. A-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17:6230-40.
23. Brummel R, Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005; 174:2429-34.
24. Brummel R, Roberts TL, Stacey KJ, Lenert P. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. Eur J Immunol 2006; 36:1951-62.
25. Hornung V, Rothenfusser S, Britsch S etal. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168:4531-7.
26. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6:823-35.
27. Savarese E, Steinberg C, Pawar RD etal. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008; 58:1107-15.
28. Lee PY, Kumagai Y, Li Y etal. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008; 205:2995-3006.
29. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25:417-28.
30. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312:1669-72.
31. Subramanian S, Tus K, Li QZ etal. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006; 103:9970-5.
32. Deane JA, Pisitkun P, Barrett RS etal. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007; 27:801-10.
33. Santiago-Raber ML, Dunand-Sauthier I, Wu T etal. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J Autoimmun 2010; 34:339-48.
34. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005; 25:29-40.
35. Wu X, Peng SL. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 2006; 54:336-42.
36. Pan ZJ, Maier S, Schwarz K etal. TLR7 modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells. Ann Rheum Dis 2010; 69:1195-9.
37. Nickerson KM, Christensen SR, Shupe J etal. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010; 184:1840-8.
38. Fairhurst AM, Hwang SH, Wang A etal. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur J Immunol 2008; 38:1971-8.
39. Pawar RD, Patole PS, Ellwart A etal. Ligands to nucleic acid-specific Toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol 2006; 17:3365-73.
40. Pawar RD, Patole PS, Zecher D etal. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2006; 17:141-9.
41. Patole PS, Gröne HJ, Segerer S etal. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005; 16:1326-38.
42. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Schlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-7.
43. Lau CM, Broughton C, Tabor AS etal. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202:1171-7.
44. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 2008; 28:799-809.
45. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36:810-16.
46. Busconi L, Bauer JW, Tumang JR etal. Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9. J Immunol 2007; 179:7397-405.
47. Goeckeritz BE, Flora M, Witherspoon K etal. Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion. Int Immunol 1999; 11:1693-700.
48. Goeken JA, Layer T, Fleenor S, Laccheo M, Lenert P. B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus. Lupus 2010; 19:1290-301.
49. Roberts TL, Turner ML, Dunn JA etal. B cells do not take up bacterial DNA: an essential role for antigen in exposure of DNA to Toll-like receptor-9. Immunol Cell Biol 2010; [Epub ahead of print] PMID: 20921967.
50. Bennett L, Palucka AK, Arce E etal. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 97:711-23.
51. Groom JR, Fletcher CA, Walters SN etal. BAFF and MyD88 signals promote a lupus like disease independent of T cells. J Exp Med 2007; 204:1959-71.
52. Sanz I, Medscape LFE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:326-37.
53. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003; 5:279-87.
54. Feng X, Wu H, Grossman JM etal. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951-62.
55. Petri M, Singh S, Tesfasyone H etal. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009; 18:980-9.
56. Baechler EC, Batliwalla FM, Karypis G etal. Interferon inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100:2610-15.
57. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheum 2005; 52:651-8.
58. Patole PS, Zecher D, Pawar RD, Grone H-J, Schlondorff D, Anders H-J. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005; 16:3273-80.
59. lpr/lpr mice in vivo. Arthritis Res Ther 2009; 11:R79.
60. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37:3582-86.
61. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007; 18:1721-31.
62. Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice. Autoimmunity 2010; 43:140-55.
63. Barrat FJ, Meeker T, Gregorio J etal. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202:1131-9.
64. Duramad O, Fearon KL, Chang B etal. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005; 174:5193-200.
65. Stunz LL, Lenert P, Peckham D etal. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol 2002; 32:1212-22.
66. Tabeta K, Hoebe K, Janssen EM etal. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006; 7:156-64.
67. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 2008; 452:234-8.
68. Kono DH, Haraldsson MK, Lawson BR etal. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA 2009; 106:12061-6.
69. Andrews BS, Eisenberg RA, Theofilopoulos AN etal. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978; 148:1198-215.
70. Vanden Bush TJ, Bishop GA. TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol 2008; 38:400-9.
71. Lenert P, Rasmussen W, Ashman RF, Ballas ZK. Structural characterization of the inhibitory DNA motif for the type A[D]-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol 2003; 22:621-31.
72. Ashman RF, Goeken JA, Drahos J, Lenert P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 2005; 17:411-20.
73. Lenert PS. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm 2010; 2010:986596.
74. Latz E, Schoenemeyer A, Visintin A etal. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190-8.
75. Haas T, Metzger J, Schmitz F etal. The DNA sugar backbone 2' deoxyribose determines Toll-like receptor 9 activation. Immunity 2008; 28:315-23.
76. Jurk M, Kritzler A, Schulte B etal. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol 2006; 36:1815-26.
77. Gorden KK, Qiu X, Batiste JJ, Wightman PP, Vasilakos JP, Alkan SS. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol 2006; 177:8164-70.